Business Wire - August 19, 2003
"I am very pleased to announce the appointment Dr. Volberding to the Immune Response Corporation's Scientific Advisory Board," said John N. Bonfiglio, Ph.D., the company's chief executive officer. "Dr. Volberding brings world-class expertise in HIV/AIDS clinical research and development to the company as we push for the commercialization of REMUNE(R), our immune-based therapeutic vaccine candidate. I look forward to working with Dr. Volberding and the other members of our newly-formed Scientific Advisory Board in this endeavor."
Dr. Volberding is a founding member and chair of the Board of Directors of the International AIDS Society-USA. He has served on numerous national committees over the course of his career including the National Academy of Sciences (Institute of Medicine) AIDS Policy Review Steering Committee, National Institutes of Health AIDS Drug Selection Committee, National Institute of Allergy and Infectious Disease, Institute of Medicine Round Table and the AIDS Clinical Trials Group Executive Committee.
Dr. Volberding co-founded one of the first AIDS-designated clinics in the early 1980s at San Francisco General Hospital, where he established a model program of AIDS patient care, research and professional education. In 1990, he co-chaired the Sixth International Conference on AIDS and has served on the International Advisory Committees for all subsequent International Conferences.
Dr. Volberding's primary research focus is the clinical trial of antiretroviral drugs. He has been instrumental in testing many compounds, but is best known for groundbreaking trials establishing standards of care for the use of zidovudine in asymptomatic HIV infection.
He is co-editor in chief of the Journal of Acquired Immune Deficiency Syndrome and co-editor of The Medical Management of AIDS, the most widely used textbook of HIV medicine, now in its sixth edition.
Dr. Volberding earned his undergraduate and medical degrees at the University of Chicago and the University of Minnesota respectively. He finished his training at the University of Utah and UCSF, where he studied for two years as a research fellow in the virology laboratory of Jay Levy, M.D., who went on to co-discover HIV/AIDS.
Other members of The Immune Response Corporation's Scientific Advisory Board include: Chairman Gilbert S. Omenn, M.D., Ph.D., professor of Internal Medicine, Human Genetics and Public Health, University of Michigan; Mario Salvatore Clerici, M.D., chair of Immunology, University of Milan; B.G. Gazzard, M.A., M.D., F.R.C.P., professor, Chelsea & Westminster Hospital in London; Eduardo Fernandez-Cruz, M.D., professor and head of the Department of Immunology, University General Hospital Gregorio Maranon in Madrid and principal investigator of the 2102 clinical trial of REMUNE(R) in Spain.
About The Immune Response Corporation and REMUNE(R)
Co-founded by medical pioneer Dr. Jonas Salk and headquartered in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company dedicated to treating HIV and AIDS through the development of REMUNE(R). REMUNE(R) is an immune-based therapeutic vaccine designed to induce an HIV-specific immune response and boost the body's natural defense mechanisms in order to slow the virus' progression. REMUNE(R) is comprised of HIV that has been chemically killed and inactivated so that it is non-infectious. During the inactivation process, the HIV outer envelope, which is prone to rapid mutations, is removed. REMUNE(R) is then emulsified in Incomplete Freund's Adjuvant, an agent that elicits a more potent immune response by drawing the immune system's attention to the inactivated virus.
HIV, the human immunodeficiency virus, is the virus that causes AIDS, a condition that slowly destroys the body's immune system, making it vulnerable to infections. More than 60 million people have been infected with HIV since it was first recognized in 1981. Today, 40 million people around the world are living with HIV.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE(R), the uncertainty of successful completion of any such clinical trials, whether REMUNE(R) will be effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE(R) in preclinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2002, and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
CONTACT: The Immune Response Corporation
Tim Warner, 202-778-1487 (Media)
Cell: 214-263-3154
Kathy Lane, 760-771-2236 (Investors)
info@imnr.com
SOURCE: The Immune Response Corporation
030819
BW030805
Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .